Articles By Anuja Singh
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…
By
Could Immix Biopharma’s Strategic Investment by Goose Capital Accelerate Breakthrough CAR-T Therapies for AL…
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has…
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio a Game-Changer for Cardiovascular Inflammation Therapies?
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire Tourmaline Bio for…
Could GE HealthCare’s FDA-Cleared Revolution™ Vibe CT System Usher in a New Era of…
Key Highlights Revolutionizing Cardiac Imaging with One-Beat ClarityGE HealthCare’s Revolution Vibe CT system has received U.S. FDA 510(k)…
Could Merck and Daiichi Sankyo’s 48% Response Rate with Ifinatamab Deruxtecan Redefine Treatment for…
Key Highlights Promising Phase 2 Data Signals Breakthrough PotentialResults from the IDeate-Lung01 trial demonstrated compelling clinical activity in…
Could Arrowhead’s $2.2B+ RNAi Collaboration with Novartis Redefine the Future of Parkinson’s and Synucleinopathies?
Key Highlights Strategic SignificanceFor Arrowhead, the deal represents its largest CNS collaboration to date, validating the TRiM™ platform’s…
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…
Could Immix Biopharma’s Strategic Investment by Goose Capital Accelerate Breakthrough CAR-T Therapies for AL…
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has…
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio a Game-Changer for Cardiovascular Inflammation Therapies?
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire Tourmaline Bio for…
Could GE HealthCare’s FDA-Cleared Revolution™ Vibe CT System Usher in a New Era of…
Key Highlights Revolutionizing Cardiac Imaging with One-Beat ClarityGE HealthCare’s Revolution Vibe CT system has received U.S. FDA 510(k)…
Could Merck and Daiichi Sankyo’s 48% Response Rate with Ifinatamab Deruxtecan Redefine Treatment for…
Key Highlights Promising Phase 2 Data Signals Breakthrough PotentialResults from the IDeate-Lung01 trial demonstrated compelling clinical activity in…
Could Arrowhead’s $2.2B+ RNAi Collaboration with Novartis Redefine the Future of Parkinson’s and Synucleinopathies?
Key Highlights Strategic SignificanceFor Arrowhead, the deal represents its largest CNS collaboration to date, validating the TRiM™ platform’s…